Aegerion Problems Mount With Poor Quarter and Reduced Guidance

CAMBRIDGE ( TheStreet) --  The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals , the company he runs as CEO, is falling apart. Shares are down 28% to $24.45 in Thursday's after-market trading session. Third quarter sales of Juxtapid, Aegerion's cholesterol-lowering drug, were 43.7 million, well off the $49 million consensus expected by the Street. Aegerion cut 2014 revenue guidance to a range of $150 million to ...